Navigation Links
Research brings us nearer to understanding how neuro cells turn cancerous
Date:7/22/2014

Scientists from the Sloan-Kettering Institute for Cancer Research in New York with the help of Plymouth University Peninsula Schools of Medicine and Dentistry have completed research which for the first time brings us nearer to understanding how some cells in the brain and nervous system become cancerous.

The results of their study are published in the prestigious journal Cancer Cell.

The research team led by Sloan-Kettering researchers studied a tumour suppressor called Merlin.

The results of the study have identified a new mechanism whereby Merlin suppresses tumours, and that the mechanism operates within the nucleus. The research team has discovered that unsuppressed tumour cells increase via a core signalling system, the hippo pathway, and they have identified the route and method by which this signalling occurs.

By identifying the signalling system and understanding how, when present, Merlin suppresses it, the way is open for research into drug therapies which may suppress the signalling in a similar way to Merlin.

Tumour suppressors exist in cells to prevent abnormal cell division in our bodies. The loss Merlin leads to tumours in many cell types within our nervous systems. There are two copies of a tumour suppressor, one on each chromosome that we inherit from our parents. The loss of Merlin can be caused by random loss of both copies in a single cell, causing sporadic tumours, or by inheriting one abnormal copy and losing the second copy throughout our lifetime as is seen in the inherited condition of neurofibromatosis type 2 (NF2).

No effective therapy for these tumours exists, other than repeated invasive surgery aiming at a single tumour at a time and which is unlikely to eradicate the full extent of the tumours, or radiotherapy.

Professor Oliver Hanemann, Director of the Institute of Translational and Stratified Medicine at Plymouth University Peninsula Schools of Medicine and Dentistry, and who led the Plymouth aspect of the study, commented: "We have known for some time that the loss of the tumour suppressor Merlin resulted in the development of nervous system tumours, and we have come tantalisingly close to understanding how this occurs. Our joint study with colleagues at the Sloan-Kettering Institute for Cancer Research shows for the first time how this mechanism works. By understanding the mechanism, we can use this knowledge to develop effective drug therapies in some cases adapting existing drugs to treat patients for whom current therapies are limited and potentially devastating."


'/>"/>
Contact: Andrew Gould
andrew.gould@plymouth.ac.uk
University of Plymouth
Source:Eurekalert

Related medicine news :

1. Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research
2. SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference
3. Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com
4. Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations”
5. Communication about female condom vital to young adults, UT Arlington researchers say
6. Chocolate Production in Canada Industry Market Research Report Now Available from IBISWorld
7. New research from Africa on pharmacomicrobiomics
8. Indoor Sports Facilities Management in the US Industry Market Research Report from IBISWorld Has Been Updated
9. Global and China Handpiece Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com
10. Benzoyl Peroxide Market Analysis for Global, China Regions – 2014 Development Trends Available at DeepResearchReports.com
11. Canadian Statistics May Help Prioritize Mesothelioma Research, According to Surviving Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: